- Home
- AEG vs QGEN Comparison
AEG vs QGEN Comparison
Compare AEG & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEG | QGEN |
|---|---|---|
| Founded | 1983 | 1986 |
| Country | Netherlands | Netherlands |
| Employees | N/A | 5700 |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | AEG | QGEN |
|---|---|---|
| Price | $7.82 | $47.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $50.68 |
| AVG Volume (30 Days) | ★ 5.5M | 1.2M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 4.79% | 3.21% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | 0.93 | ★ 1.84 |
| Revenue | ★ $15,344,685,849.00 | $2,070,781,000.00 |
| Revenue This Year | N/A | $7.12 |
| Revenue Next Year | $2.04 | $6.13 |
| P/E Ratio | ★ $8.28 | $25.56 |
| Revenue Growth | 2.83 | ★ 5.32 |
| 52 Week Low | $5.42 | $37.63 |
| 52 Week High | $8.15 | $51.88 |
Technical Indicators
Market Signals| Indicator | AEG | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 55.46 |
| Support Level | $7.81 | $46.39 |
| Resistance Level | $7.99 | $48.13 |
| Average True Range (ATR) | 0.10 | 0.67 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 65.83 | 68.53 |
Price Performance
Historical ComparisonAbout AEG Aegon Ltd. New York Registry Shares
Aegon is a life insurance and long-term savings business listed in the Netherlands. It listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. Over recent years, Aegon has been moving through an extensive transformation program where management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the group that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile-earnings products and recycle funds into capital-light and more predictable strategic businesses.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).